EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

PD-L1 Expression in Gliomas: A Potential Immunotherapeutic Target in High-grade Tumours

Ayushi Agarwal, Charanjeet Ahluwalia, Kepeemadam Balasubramanyam Shankar, Sana Ahuja

Prague Medical Report · 2026 · 127 (1) · 21-26

DOI: 10.14712/23362936.2026.3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Prague Medical Report, online erschienen am 17.03.2026. Verfasst von Ayushi Agarwal und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, India. Hauptthemen laut MEDLINE: B7-H1 Antigen, Glioma, Brain Neoplasms. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Gliomas are the most common primary tumours of the central nervous system, with glioblastoma (grade 4 glioma) being the most malignant form. Despite standard therapy, patient survival remains poor. Immune checkpoint blockade targeting the PD-1/PD-L1 axis has shown promise in other cancers, but its role in gliomas remains under investigation. This study evaluates PD-L1 expression in gliomas and its correlation with tumour grade. A total of 50 histologically confirmed glioma cases were studied. Tumours were graded according to WHO 2021 CNS classification, and immunohistochemistry (IHC) was performed using antibodies for IDH, ATRX, TP53, Ki67, and PD-L1. PD-L1 expression was scored using an immunoreactivity scale, and its association with tumour grade was analysed using ordinal regression. A p-value < 0.05 was considered statistically significant. Among the 50 gliomas, the majority were astrocytoma, IDH-mutant (54%) followed by glioblastoma, IDH-wild type (26%). Most tumours were grade 4 (44%), grade 2 (34%), or grade 3 (18%). PD-L1 expression was detected exclusively in grade 4 tumours, with 6 of 22 (27.27%) cases showing positive expression. No expression was noted in grade 1–3 tumours. The association between PD-L1 expression and tumour grade was statistically significant (p=0.007). PD-L1 expression is limited to high-grade (grade 4) gliomas, suggesting a role in immune evasion. These findings support the potential utility of PD-L1 as a biomarker to identify glioma patients who may benefit from anti-PD-1/PD-L1 immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

B7-H1 AntigenGliomaBrain NeoplasmsHumansFemaleMaleNeoplasm GradingMiddle AgedImmunohistochemistryAdultAgedBiomarkers, Tumor

Stichwörter der Autor:innen

GliomasGradeImmunotherapyPD-L1

Substanzen

B7-H1 AntigenCD274 protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Pathology, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, India.
  • Department of Neurosurgery, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, India.
  • Department of Pathology, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, India. sanaahuja11@yahoo.com.

Zitieren

APA

Agarwal, A., Ahluwalia, C., Shankar, K. B., & Ahuja, S. (2026). PD-L1 Expression in Gliomas: A Potential Immunotherapeutic Target in High-grade Tumours. Prague Medical Report, 127(1), 21-26. https://doi.org/10.14712/23362936.2026.3

Vancouver

Agarwal A, Ahluwalia C, Shankar KB, Ahuja S. PD-L1 Expression in Gliomas: A Potential Immunotherapeutic Target in High-grade Tumours. Prague Medical Report. 2026;127(1):21-26. doi:10.14712/23362936.2026.3

BibTeX
@article{Agarwal2026,
  author = {Agarwal, Ayushi and Ahluwalia, Charanjeet and Shankar, Kepeemadam Balasubramanyam and Ahuja, Sana},
  title = {PD-L1 Expression in Gliomas: A Potential Immunotherapeutic Target in High-grade Tumours},
  journal = {Prague Medical Report},
  year = {2026},
  volume = {127},
  number = {1},
  pages = {21--26},
  doi = {10.14712/23362936.2026.3}
}
Kostenlos starten →